# NAD+ support and blood sugar: separate the ingredients

NAD-related compounds have different evidence. A muscle insulin-sensitivity result is not the same as proven blood-sugar treatment.

Canonical: https://velri.co/blog/nad-support-blood-sugar-glucose-question-road-warrior
Publisher: Velri (https://velri.co/about)
Published: 2026-07-10
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

There is no single blood-sugar effect that can be assigned to every product described as NAD+ support. Studies involve different ingredients, populations and outcomes. Some findings concern insulin sensitivity in muscle; others concern adverse effects from high-dose niacin. [1][2]

Those results need to stay attached to the compound that was studied.

## What did the NMN trial measure?

A 10-week randomized trial studied NMN in postmenopausal women with prediabetes who had overweight or obesity. Insulin-stimulated glucose disposal and muscle insulin signaling increased after NMN treatment; they did not change after placebo. [1]

The measurement used a specialized research method. The finding concerns muscle insulin sensitivity in that group, not demonstrated diabetes treatment with NAD+ injections. [1]

## Why can niacin raise a different concern?

At high supplemental amounts, nicotinic acid can impair glucose tolerance and increase insulin resistance. NIH guidance discusses checking glucose or HbA1c alongside other safety measurements in that setting. [2]

That adverse-effect evidence concerns nicotinic acid. It should not be used to declare that every NAD+ precursor raises glucose, just as the NMN trial should not be used to promise that every precursor lowers it. [1][2]

## Which glucose result answers the clinical question?

Prediabetes and diabetes are usually assessed with HbA1c, fasting plasma glucose or an oral glucose-tolerance test. NIDDK notes that direct testing for insulin resistance is used mainly in research. [3]

If you have a glucose-related concern, the discussion should include existing results, medicines and the exact supplement being considered. The evidence should explain whether it concerns safety monitoring, a research signal or a demonstrated treatment effect. Those are three different reasons for looking at the same part of metabolism.

## Sources
[1] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (2021). https://pubmed.ncbi.nlm.nih.gov/33888596/
[2] Niacin - Health Professional Fact Sheet (2025). https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/?uid=f4727f1be0442s16
[3] Insulin Resistance & Prediabetes - NIDDK (2025). https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support